Matthew J Pianko, MD
Clinical Associate Professor of Internal Medicine
Department of Internal Medicine, Division of Hematology/Oncology
1500 East Medical Center Drive, C365 Med Inn Bldg.
Ann Arbor, Michigan 48109-5848
[email protected]

Available to mentor
Matthew J Pianko, MD
Clinical Associate Professor
  • About
  • Links
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
    • About

    I am a hematologist and clinical investigator with a focus on multiple myeloma and other plasma cell disorders. My research interests focus on understanding and reducing the burden of infections in patients with multiple myeloma, particularly older adults.

    Links
    Qualifications
    • Fellowship, Hematology and Medical Oncology
      Memorial Sloan Kettering Cancer Center, Department of Medicine, 2018
    • Resident, Internal Medicine
      NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, Department of Medicine, 2014
    • Internship, Internal Medicine
      NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, Department of Medicine, 2012
    • Medical Doctorate
      Stanford University, 291 Campus Drive, 2011
    • Bachelor of Science with High Honors in Biology
      University of Michigan, Ann Arbor, MI, 2006
    Center Memberships
    • Center Member
      Institute for Healthcare Policy and Innovation
    Research Overview

    Infections, Immunity, Immunotherapy, Clinical trials, Geriatric Oncology

    Recent Publications See All Publications
    • Journal Article
      Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.
      Pianko MJ, Funt SA, Page DB, Cattry D, Scott EC, Ansell SM, Borrello IM, Gutierrez M, Lendvai N, Hassoun H, Landgren CO, Lesokhin AM. Leuk Lymphoma, 2018 Jan; 59 (1): 221 - 224. DOI:10.1080/10428194.2017.1320713
      PMID: 28554253
    • Preprint
      Complement C3d enables protective immunity capable of distinguishing spontaneously transformed from non-transformed cells
      Platt JL, Zhao C, Chicca J, Pianko MJ, Han J, The S, Rao A, Keller E, de Mattos Barbosa MG, Naing L, Pasieka-Axenov T, Axenov L, Schaefer S, Farkash E, Cascalho M. bioRxiv, DOI:10.1101/2024.07.31.606044
    • Journal Article
      Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
      Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, Zonder JA, Shah MR, Lentzsch S, Baz R, Maly JJ, Namburi S, Pianko MJ, Ye JC, Wu KL, Silbermann R, Min C-K, Vekemans M-C, Munder M, Byun JM, Martínez-Lopez J, Cassady K, DeVeaux M, Chokshi D, Boyapati A, Hazra A, Yancopoulos GD, Sirulnik LA, Rodriguez Lorenc K, Kroog GS, Houvras Y, Dhodapkar MV. J Clin Oncol, 2024 Aug 1; 42 (22): 2702 - 2712. DOI:10.1200/JCO.24.01008
      PMID: 38879802
    • Preprint
      Colesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma.
      Hultcrantz M, Hassoun H, Korde N, Maclachlan K, Mailankody S, Patel D, Shah U, Tan CR, Chung DJ, Lahoud O, Landau H, Scordo M, Shah GL, Giralt S, Pianko MJ, Burge M, Barnett K, Salcedo M, Caple J, Tran L, Blaslov J, Shekarkhand T, Hamid S, Nemikovski D, Derkach A, Arisa O, Peer CJ, Figg WD, Usmani SZ, Landgren O, Lesokhin AM. 2024 Jun 5; DOI:10.21203/rs.3.rs-4406606/v1
      PMID: 38883739
    • Proceeding / Abstract / Poster
      Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9
      Sborov D, Pawlyn C, Ishida T, Huang JSY, Benjamin R, Iida S, Popat R, Kuroda J, Pianko M, Ramakrishnan A, Schuster SR, Dabak VS, Lesokhin A, Conte U, Soltantabar P, Hong F, Vandendries E, Fonseca R. Journal of Clinical Oncology, 2024 Jun 1; 42 (Issue 16_suppl): DOI:10.1200/JCO.2024.42.16_suppl.7522
    • Journal Article
      Abstract CT001: Linvoseltamab, a B-cell maturation antigen-targeted T-cell-engaging bispecific antibody, induces deep and durable responses in patients with relapsed or refractory multiple myeloma including difficult-to-treat subgroups
      Jagannath S, Richter J, Dhodapkar MV, Hoffman JE, Lee HC, Suvannasankha A, Shah MR, Lentzsch S, Zonder JA, Baz R, Maly JJ, Namburi S, Wu KL, Pianko M, Silbermann R, Min C-K, Vekemans M-C, Munder M, Byun JM, Lopez JM, DeVeaux M, Chokshi D, Boyapati A, Hazra A, Lorenc KR, Kroog GS, Houvras Y, Bumma N. Cancer Research, 2024 Apr 5; 84 (7_Supplement): ct001 - ct001. DOI:10.1158/1538-7445.am2024-ct001
    • Journal Article
      Lenalidomide in the treatment of anti-myelin-associated glycoprotein neuropathy: A phase 1 study to identify the maximum tolerated dose.
      Stino AM, Bumma N, Smith R, Davalos L, Allen J, Ye JC, Pianko M, Campagnaro E, Fierro C, Awad A, Murdock B, Pietrzak M, Loszanski G, Kline DM, Efebera Y, Elsheikh B. Eur J Neurol, 2024 Mar; 31 (3): e16164 DOI:10.1111/ene.16164
      PMID: 38015467
    • Journal Article
      Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis.
      Khouderchah CJ, Ochs M, Pianko M, Mahmoudjafari Z, Snyder J, Ahmed I, Campagnaro E, Nachar VR. J Oncol Pharm Pract, 2024 Apr 5; 10781552241242022 DOI:10.1177/10781552241242022
      PMID: 38576408